Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.96Accent Microcell Ltd demonstrates robust financial health, characterized by exceptional growth and outstanding profitability. The company is expanding at a very rapid pace across sales, profits, and its asset base, indicating strong market demand and successful strategic execution. Its profitability is a key strength, with high margins and excellent returns on investment. Furthermore, the company operates with virtually no debt, giving it a superior level of long-term financial stability and very low risk. However, this rapid growth presents challenges in operational efficiency. A notable weakness is the significant amount of time it takes to collect payments from customers, which could strain cash flow. Additionally, the overall effectiveness of using its large capital base to generate sales is low. The company is heavily reinvesting its earnings into expansion, as shown by high capital spending and low dividend payouts. The future outlook is positive, driven by strong growth momentum, but hinges on managing operational efficiencies as it scales.
Health Score : 7.96Accent Microcell Ltd demonstrates robust financial health, characterized by exceptional growth and outstanding profitability. The company is expanding at a very rapid pace across sales, profits, and its asset base, indicating strong market demand and successful strategic execution. Its profitability is a key strength, with high margins and excellent returns on investment. Furthermore, the company operates with virtually no debt, giving it a superior level of long-term financial stability and very low risk. However, this rapid growth presents challenges in operational efficiency. A notable weakness is the significant amount of time it takes to collect payments from customers, which could strain cash flow. Additionally, the overall effectiveness of using its large capital base to generate sales is low. The company is heavily reinvesting its earnings into expansion, as shown by high capital spending and low dividend payouts. The future outlook is positive, driven by strong growth momentum, but hinges on managing operational efficiencies as it scales.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
23.12
Industry Median
36.13
Small Cap Median
35.79
P/E RATIO
24.25
P/B RATIO
3.21
Industry Median
6.08
Small Cap Median
6.08
P/S RATIO
3.03
Industry Median
5.75
Small Cap Median
5.17
Others
PEG RATIO
0.47
EV/EBITDA RATIO
16.71
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹334.1 as on May 29, 2026.
Growth Score : 10.00The company is in a phase of exceptional and widespread growth. It is expanding at an extremely high rate across all major indicators, including revenue, operating profit, and earnings per share. This powerful growth trajectory is supported by a rapid expansion of its asset base, indicating strong market acceptance and successful execution of its expansion strategy. This is a primary strength of the company.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 24.81 | 18.67 | 24.87 | 7.72 | 31.7 |
| Operating Profit Growth Rate | 18.18 | 46.15 | 105.26 | 7.69 | 35.71 |
| Earnings Per Share (EPS) Growth | -59.08 | 105.99 | 52.18 | 9.63 | 32.66 |
| Asset Growth Rate | 17.28 | 16.84 | 84.68 | 11.22 | 41.23 |
| Net Income Growth Rate | 20 | 100 | 150 | 10 | 33.33 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 5 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 8 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 13 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 18 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Accent Microcell Ltd. is a leading global manufacturer and exporter of high-quality Microcrystalline Cellulose (MCC), a versatile excipient used in pharmaceuticals, food, and cosmetic industries. The company caters to a diverse international client base across over 45 countries, establishing itself as a significant player in the specialty chemicals sector.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Accent Microcell Ltd's P/E ratio (TTM) is 23.12, compared to the industry median of 36.13 and large cap median of 35.79.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Accent Microcell Ltd's P/B ratio is 3.21, compared to the industry median of 6.08 and large cap median of 6.08.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Accent Microcell Ltd's P/S ratio is 3.03, compared to the industry median of 5.75 and large cap median of 5.17.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Accent Microcell Ltd's PEG ratio is 0.47.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Accent Microcell Ltd's EV/EBITDA ratio is 16.71.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Accent Microcell Ltd's ROE is 15.94%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Accent Microcell Ltd's ROA is 17.70%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Accent Microcell Ltd's ROCE is 25%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Accent Microcell Ltd's operating margin is 16.33%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Accent Microcell Ltd's net margin is 12.61%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Accent Microcell Ltd's current ratio is 3.67.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Accent Microcell Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Accent Microcell Ltd's interest coverage ratio is 59.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Accent Microcell Ltd's DPS is ₹0.91.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Accent Microcell Ltd's EPS is 32.66.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹334.10. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2001
Headquarters: Ahmedabad, Gujarat
Core Offerings: Microcrystalline Cellulose (MCC) for pharmaceutical excipients, MCC for food additives, MCC for cosmetic applications, Specialty MCC grades
Stock Listing: NSE (ACCENTMIC), BSE ({bse})
Promoter: Vasant Vala, Ghanshyam Patel, Nitin Patel
• 2001: Incorporated as Accent Microcell Private Limited. • 2007: Established its first manufacturing facility in Pirana, Ahmedabad. • 2018: Expanded operations with a second manufacturing facility in Dahej, Gujarat. • 2021: Began commercial production at the third manufacturing facility in Dahej. • 2023: Converted to a public limited company and successfully completed its SME IPO on NSE Emerge in December. • 2024: Migrated to the Main Board of NSE and BSE in February.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Microcrystalline Cellulose (MCC) Manufacturing | 100% | N/A (company-wide EBITDA is reported) |
Microcrystalline Cellulose (MCC) Products: Manufactures various grades of MCC primarily used as excipients in pharmaceutical formulations, binders and disintegrants in tablets and capsules.
Diversified Applications: Offers MCC for diverse applications including food additives (thickening, stabilizing, anti-caking agents), cosmetic formulations, and other industrial uses.
Global Presence: Exports to over 45 countries, ensuring high quality and regulatory compliance (e.g., cGMP, FSSC, Kosher, Halal certifications).
Manufacturing Facilities: Operates three state-of-the-art manufacturing facilities located in Pirana and Dahej, Gujarat, India, with robust production capacities.
Mr. Vasant Vala (Chairman & Whole-time Director): A co-founder, he has over two decades of experience in the chemical and pharmaceutical excipients industry, driving strategic growth and vision. Mr. Ghanshyam Patel (Managing Director): A co-founder, he possesses extensive expertise in production and operations management, playing a crucial role in optimizing manufacturing processes. Mr. Nitin Patel (Whole-time Director): A co-founder, he focuses on sales, marketing, and business development, expanding the company's domestic and international market reach.
No major subsidiaries reported.
Successfully completed its SME IPO on NSE Emerge in December 2023, followed by migration to the Main Board of NSE and BSE in February 2024.
The Accent Microcell Ltd share price today is ₹334.10 on NSE (ACCENTMIC), as of 26 Sept 2026.
As of 25 Sept 2026, Accent Microcell Ltd share price is ₹334.10, with previous close ₹334.10. Today's range is ₹334.10 to ₹334.10. The 52-week range is ₹303 to ₹731.70.
As of today, Accent Microcell Ltd's market cap is ₹801.84 crore (Small Cap).
Accent Microcell Ltd's current P/E ratio is 23.12, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 30.
Accent Microcell Ltd's current P/B ratio is 3.21.
Accent Microcell Ltd's current dividend yield is 0.27%. Last dividend of ₹0.00 per share was declared on N/A.
Accent Microcell Ltd's EPS (TTM) is ₹32.66.
Accent Microcell Ltd. is a leading global manufacturer and exporter of high-quality Microcrystalline Cellulose (MCC), a versatile excipient used in pharmaceuticals, food, and cosmetic industries. The company caters to a diverse international client base across over 45 countries, establishing itself as a significant player in the specialty chemicals sector.
Accent Microcell Ltd is promoted by Vasant Vala, Ghanshyam Patel, Nitin Patel, holding 55.47% as of 25 Sept 2026.
Accent Microcell Ltd is listed on NSE (ACCENTMIC) and BSE ({bse}). Its next quarterly results are expected on August 2024 (Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)
Dividend Per Share (DPS)
